You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
News and reporting on lung cancer.
The company was cleared to begin a Phase I/II trial of its lead candidate, a therapeutic vaccine that can potentially treat and prevent recurrence of KRAS-mutated cancers.
The Epidemiology of Young Lung Cancer study will build on a prior genomics study to better characterize NSCLC patients diagnosed before age 40.
The Chinese company will use the funds to accelerate the registration and commercialization of its NGS-based products for cancer screening and early detection.
The Spanish firm also expects to release clinical data on its early-stage, next-generation sequencing-based colorectal cancer test in the first half of 2021.
News items for the week of Jan. 25, 2021.
The study, which showed that the disease may not only result from tobacco exposure as previously thought, could lay the groundwork for targeted therapies.
Natera alleges Inivata infringes its US Patent Nos. 10,262,755 and 10,597,709, which cover cancer monitoring and molecular residual disease testing.
The startup biotech has spent four years researching PRDM genes in various cancers and is coming out of stealth mode with a lead candidate in lung cancer.
AmoyDx will develop and seek regulatory approval in China for a lung cancer PCR panel to be used with Merck's MET inhibitor tepotinib.
The Universities of Southampton and Leeds will lead the project with participation from Johnson & Johnson, Roche, Oncimmune, BC Platforms, Inivata, and NHS England.